A
Adverum Biotechnologies
Clinical stage gene therapy targeting unmet needs in ocular and rare diseases with durable therapeutic protein expression
About Adverum Biotechnologies
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company focused on addressing unmet medical needs in ocular and rare diseases. The company develops gene therapy product candidates that aim to provide long-lasting efficacy by inducing sustained expression of therapeutic proteins. Adverum's core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, particularly in scalable process development.
Read full description
Adverum operates in the biotechnology sector, serving patients with serious ocular conditions and rare diseases. The company's business model revolves around the development and commercialization of gene therapy treatments. Revenue is primarily generated through partnerships, licensing agreements, and potential future sales of approved therapies.
The company has recently completed patient enrollment for its INFINITY Phase 2 trial of ADVM-022 in diabetic macular edema (DME) and announced the establishment of a new GMP gene therapy manufacturing facility. These developments highlight Adverum's commitment to advancing its pipeline and expanding its manufacturing capabilities.
At a glance
- Status
- Closed
- Founded
- 2012
- Headquarters
- Redwood City, United States
- Listing
- IPO 2014
- Employees
- 143
- Open positions
- 10
- Dealroom signal
- 0.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Genetics and genomics, Eye Diseases, Spinout, Biotech and Pharma, Rare Diseases, biotech medtech and e-health, Observatoire Deeptech, observatoire industrial tech
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest May 2016
- Capital deployed
- —
- Preferred round
- ACQUISITION
Latest news
Press, funding announcements and product moves mentioning Adverum Biotechnologies.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Oct 2025 | $0 | — | Eli Lilly | ↗ |
| PRIVATE PLACEMENT VCOther financing | Feb 2024 | $128M | — | 5AM Ventures · Vivo Capital · Samsara BioCapital · Logos Capital | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $1M | 0% | −$136M | -13550.6% |
| 2025 | $1M | 0% | −$136M | -13550.6% |
| 2024 | $1M | -72.2% | −$136M | -13550.6% |
| 2023 | $3.6M | — | −$118M | -3287.4% |
| 2022 | $0 | -100% | −$151M | — |
| 2021 | $7.5M | — | −$141M | -1886.4% |
| 2020 | $0 | — | −$114M | — |
Growth signals
Latest recorded traffic for Adverum Biotechnologies is 2.7K monthly website visits, down 47.1% over the last three months. Adverum Biotechnologies's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Other known investors11 additional known investors
5AM Ventures
CNRS Innovation
Commodore Capital
Eli Lilly
Frazier Life Sciences
French National Centre for Scientific Research - CNRS
Logos Capital
Samsara BioCapital
TCGX- VPVenrock Healthcare Capital Partners
Vivo Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Adverum Biotechnologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Adverum Biotechnologies’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.